In hyperparathyroidism, which vitamin D metabolite should be measured: 25‑hydroxyvitamin D or 1,25‑dihydroxyvitamin D?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Measure 25-Hydroxyvitamin D, Not 1,25-Dihydroxyvitamin D

In hyperparathyroidism, you should check 25-hydroxyvitamin D (25-OH-D), not 1,25-dihydroxyvitamin D. This is explicitly stated in multiple guidelines and supported by the underlying pathophysiology 1, 2.

Why 25-Hydroxyvitamin D is the Correct Test

25-hydroxyvitamin D is the measure of body vitamin D stores, while 1,25-dihydroxyvitamin D does not reflect vitamin D status 1, 2. The Endocrine Society guidelines are unequivocal: "We recommend against using the serum 1,25(OH)₂D assay for this purpose" when evaluating vitamin D status 2.

The Pathophysiology Explains Why

In hyperparathyroidism, elevated PTH drives increased conversion of 25-OH-D to 1,25-dihydroxyvitamin D through enhanced 1-alpha-hydroxylase activity 1. This creates a paradoxical situation:

  • 1,25-dihydroxyvitamin D levels are frequently normal or even elevated in patients with vitamin D deficiency who have hyperparathyroidism, due to secondary hyperparathyroidism driving conversion 2
  • The elevated 1,25-dihydroxyvitamin D consumes the 25-OH-D substrate, leading to low 25-OH-D levels 3, 4
  • This means 1,25-dihydroxyvitamin D will mislead you into thinking vitamin D status is adequate when it is not

Research confirms this: patients with primary hyperparathyroidism have significantly elevated free 1,25-dihydroxyvitamin D levels and increased "activation ratios" (1,25-OH-D/25-OH-D) despite having low 25-OH-D stores 5, 6. One study found the activation ratio was 3-fold higher in hyperparathyroidism patients qualified for surgery compared to controls 6.

Clinical Application

Check 25-hydroxyvitamin D at first encounter if PTH is elevated 1. The K/DOQI guidelines recommend:

  • If 25-OH-D is <30 ng/mL, initiate vitamin D supplementation 1
  • Repeat annually once replete 1
  • Monitor calcium and phosphorus every 3 months during supplementation 1

Important Caveats

Vitamin D supplementation in primary hyperparathyroidism requires careful calcium monitoring 2. The Endocrine Society acknowledges that most patients will not increase their serum calcium significantly, and PTH may even decrease, but calcium should be monitored 2. Research shows vitamin D supplementation can exaggerate hypercalcemia in some patients with primary hyperparathyroidism 3, 7.

Discontinue all vitamin D therapy if:

  • Corrected total calcium exceeds 10.2 mg/dL (2.54 mmol/L) 1
  • Phosphorus exceeds 4.6 mg/dL and persists despite phosphate binders 1

The only time to measure 1,25-dihydroxyvitamin D is for monitoring specific inherited disorders of vitamin D metabolism, chronic kidney disease, or granulomatous disorders—not for assessing vitamin D status 2.

References

Related Questions

Given a 25‑hydroxy‑vitamin D level of 23 ng/mL, a calcium level of 10.2 mg/dL, and an intact parathyroid hormone level of 102 pg/mL, does this represent acceptable primary hyperparathyroidism?
Vitamin D increased from 14 ng/mL to 24 ng/mL while parathyroid hormone (PTH) remains elevated (135 pg/mL → 133 pg/mL); should hyperparathyroidism be investigated?
Can a 19-year-old patient have mild hypercalcemia with a normal serum 25‑hydroxyvitamin D level?
What is the most likely explanation for a 16‑year‑old male with low serum calcium, elevated parathyroid hormone, normal magnesium, and normal 25‑hydroxyvitamin D?
In a 67‑year‑old woman with epigastric burning discomfort, nausea, mild hypercalcemia, normal vitamin D, elevated intact parathyroid hormone, hypercalciuria, and a history of tarsal bone fractures, hysterectomy, and endometrial ablation, what is the differential diagnosis for the hypercalcemia?
What does an elevated alkaline phosphatase with increased liver and bone fractions signify?
What additional medications can be used to manage pain and urinary symptoms in a patient with a ureteral stent confirmed by CT, who is already taking gabapentin and hydroxyzine and is under urology follow‑up?
In a six-year-old child with a serum 25‑hydroxyvitamin D level of 28 ng/mL, what vitamin D3 supplementation dose is appropriate?
How can duloxetine be safely tapered while initiating aripiprazole and Lexapro (escitalopram)?
What are the other indications for prone positioning in patients with severe hypoxemic respiratory failure?
When should thyroid‑stimulating hormone (TSH) be rechecked after adjusting levothyroxine dose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.